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background: Functional mitral valve regurgitation (MR) remains a clinical challenge in patients with high operative risk. Evidence to date suggests 
poor outcomes with medical therapy alone, but data regarding MR and left ventricular (LV) systolic function changes over time among medically 
managed high risk patients are limited.
objective: To study the progression of MR severity and LV function in patients with medically managed significant MR at high surgical risk who 
survived at least 6 months.
methods: Between January 1st, 2000 and Dec 31st, 2012, we identified patients with medically managed moderate to severe MR that fulfilled the 
EVEREST II High Risk Registry (HRR) criteria. All patients were selected based on optimal propensity matching and were additionally required to have 
a follow up echocardiogram > 6 months from the index study. Demographic, clinical and echocardiographic data was compared between baseline 
and follow up. Paired measurements of global longitudinal strain (GLS) were obtained in a subset of patients with suitable image quality.
results: A total of 159 patients (mean age 73.5, female 45%) fulfilled the study criteria of whom 130 (81%) and 29 patients (19%) had 
moderate and severe MR respectively. Median STS score was 8.9 (IQR: 5.2-14.8) and beta blockers as well as ACEI/ARB was used by 71% and 73% 
respectively. During a median follow-up of 441 days (IQR: 272-780), MR decreased in severity in 82 patients (51.6%) and remained unchanged or 
worsened in 77 patients (49.4%) Among patients with moderate MR at baseline, improvement was seen in 62 (47.5%), worsening in 6 (5%), and 
unchanged severity in 62 (47.5%). Among patients with severe MR at baseline, improvement was seen in 17 (58.5%) and 12 (41.5%) remained 
unchanged. Median LVEF did not change from baseline to follow-up (45%; IQR: 30-55 vs. 45%, IQR: 30-55, p=0.51). Among 43 patients with 
evaluable paired GLS measurements, GLS did not significantly change over time (-11.8 to -12.6; p=0.36).
conclusions: While medically treated patients with significant MR have substantial mortality, among survivors a substantial number improve MR 
grade and EF in follow up.
 
